Deep phenotyping of childhood paroxysmal events

  • Research type

    Research Study

  • Full title

    Effect of paroxysmal events in early onset neurological disease on cerebral tissue oxygenation & metabolism: a NIRS pilot study

  • IRAS ID

    232119

  • Contact name

    J Helen Cross

  • Contact email

    h.cross@ucl.ac.uk

  • Sponsor organisation

    GREAT ORMOND STREET HOSPITAL FOR CHILDREN NHS FOUNDATION TRUST

  • Duration of Study in the UK

    0 years, 11 months, 31 days

  • Research summary

    The infantile epilepsies and alternating hemiplegia of childhood (AHC) are rare progressive childhood disorders sharing an often-poor prognosis with regard to long-term neurological function and development. Both conditions are characterized by frequent recurring paroxysmal events, epileptic seizures in infantile epilepsy and hemiplegic, plegic and dystonic episodes as well as epileptic seizures in AHC. It is assumed that these paroxysmal events play a role in the development of the long-term impairment of these patients. However there is little evidence so far proving this assumption. A possible mechanism could be energy depletion in the brain cells during the paroxysmal events.

    Non-invasive in-vivo markers of metabolism have not been available until recently. However recent advances in broadband-Near-infrared spectroscopy (NIRS) have made such measurements possible. We will perform the first broadband-NIRS measurements with simultaneous EEG in this patient group to measure changes in hemodynamics (oxygenated and deoxygenated hemoglobin (Δ[HbO2 ] and Δ[HbR]) and energetics (the oxidation state of cytochrome-c-oxidase (Δ[oxCCO], an enzyme involved in cell metabolism) in the brain before and during paroxysmal events.

    If broadband-NIRS allows us to establish an unusual metabolic response of energy depletion during paroxysmal events in our children this could be the mechanism paroxysmal events drive brain injury. Further studies would then be initiated powered to determine whether this method can be used as a reliable biomarker of the events' severity, children' neurodevelopment prognosis and therefore as a useful marker guide therapeutic intervention.

  • REC name

    London - Bloomsbury Research Ethics Committee

  • REC reference

    17/LO/1402

  • Date of REC Opinion

    30 Oct 2017

  • REC opinion

    Further Information Favourable Opinion